Record mula sa primary source
Decision-gradeTopline na resulta
Ultragenyx: Inaasahan ang final analysis ng Phase 3 Orbit/Cosmic para sa UX143 sa katapusan ng 2025
Sinabi sa dokumento na ang Phase 3 Orbit at Cosmic studies ng setrusumab (UX143) sa osteogenesis imperfecta ay patuloy na nagpapatuloy patungo sa final analyses pagkatapos na ang mga pasyente ay nasa therapy nang hindi bababa sa 18 buwan. Ang data mula sa mga pag-aaral na ito ay inaasahan sa pagtatapos ng 2025.
Mahahalagang fact
- Na-file
- Nob 4, 2025, 09:12 PM
- Kaganapan
- Topline na resulta
- Direksyon
- Neutral
- Kumpanya
RAREUltragenyx- Asset
- setrusumab
- Pinagmulan
- SEC 8-K
- Kumpiyansa
- May source
Sipi mula sa source
EX-99.1 2 rare-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Contacts Ultragenyx Pharmaceutical Inc. Investors Joshua Higa ir@ultragenyx.com Ultragenyx Reports Third Quarter 2025 Financial Results and Corporate Update Third quarter total revenue of $160 million, Crysvita® revenue of $112 million and Dojolvi® revenue of $24 million Reaffirm 2025 Revenue Guidance: Total revenue between $640 million to $670 million, Crysvita revenue of $460 million to $480 million, and Dojolvi revenue of $90 million to $100 million Bolstered balance sheet with $400 million proceeds from sale of portion of Crysvita royalty interest NOVATO, Calif. – November 04, 2025 – Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies